ADMA Biologics, Inc. ADMA
12.74 USD -0.05 (-0.39%)
Nov 10, 2026, 10:33 AM EST
12.69 Day range 12.95
7.21 52-week range 20.46
- YTD
- -30.15%
- 1 year
- -13.39%
News
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
benzinga.com ADMA Biologics CEO Says Star Drug ASCENIV Is Just Getting Started ADMA Biologics stock surges 23% after beating Q3 2026 earnings, led by a 31% rise in ASCENIV demand and strong margins.
benzinga.com Motorola Solutions, Sezzle, Unity Software, Toyota Motor And Other Big Stocks Moving Higher On Thursday U.S. stocks were mixed as Nasdaq fell over 3%, while Motorola Solutions and other companies surged on strong earnings and raised guidance.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
benzinga.com Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket AppLovin surged 16.5% premarket after Q3 revenue and EPS beat estimates and Q4 guidance topped forecasts; MNTN plunged 42.3% on weak results.
benzinga.com Cantor Fitzgerald Maintains Neutral on ADMA Biologics, Raises Price Target to $13 Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Neutral and raises the price target from $12 to $13.
benzinga.com ADMA Biologics (ADMA) Shares Jump 28% After-Hours: Here’s Why ADMA Biologics shares surge after Q3 earnings growth as the company raises 2026 profit guidance.
seekingalpha.com ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
zacks.com Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates Adma Biologics (ADMA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
marketbeat.com ADMA Biologics Q3 Earnings Call Highlights ADMA Biologics NASDAQ: ADMA raised its minimum full-year earnings expectations after third-quarter profit rose on stronger sales of ASCENIV and improved manufacturing yields, even as competitive…
benzinga.com ADMA Biologics Q3 2026 Earnings Call Transcript ADMA Biologics (NASDAQ:ADMA) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com ADMA Biologics Q3 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $141.102M Beat $138.190M Estimate ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.20 by 15 percent. This is a 43.75 percent increase over earnings of $0.16…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
globenewswire.com ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update 3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37%…
benzinga.com ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.- benzinga.com ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of…
benzinga.com Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17 Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $20 to $17.
benzinga.com Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, semiconductors, biotech stocks during Q1.- benzinga.com Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18 Canaccord Genuity analyst Gary Nachman maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowers the price target from $21 to $18.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.- benzinga.com Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20 Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $24 to $20.
benzinga.com Why Kulicke And Soffa Industries Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other gainers include Global Engine, Agilon Health, and Blue Bird Corp.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com ADMA Biologics Sees FY2026 Sales $530.000M-$560.000M vs $632.367M Est ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $530.000 million-$560.000 million vs $632.367 million analyst estimate.
- benzinga.com ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.20 by 15 percent. This is a 21.43 percent increase over earnings of $0.14…
benzinga.com ADMA Biologics Announces FDA Approval Of The Company's Supplemental Biologics License Application Submitted Under Section 351(a) Of The Public Health Service Act For ASCENIV The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment.Additionally, the approval provides for a revision of ASCENIV's…
benzinga.com Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21 Canaccord Genuity analyst Gary Nachman initiates coverage on ADMA Biologics (NASDAQ:ADMA) with a Buy rating and announces Price Target of $21.
benzinga.com Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend. Other gains: AGX 35.5%, MSC 24.5%, ADMA 13%, SGML 12.2%, KOD 10.5%, TBN 9.9%, METC 8.8%, U 8.3%,…
benzinga.com ADMA Biologics Slams Short Seller Claims, Highlights Strong Demand ADMA Biologics stock rebounds premarket after a 30% drop tied to short seller claims, as the company defends demand and financial reporting.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com ADMA Biologics Rebuts Short Seller Claims, Defends Product Demand ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics,…
benzinga.com Why Are Shares Of ADMA Biologics Falling Today? ADMA Biologics, Inc. (NASDAQ: ADMA) shares are tumbling on Thursday as traders lean into risk-off positioning and punish weaker charts in a down tape. The Nasdaq is down 0.91% while the S&P 500 has…
benzinga.com This Qualcomm Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See what analysts think about QCOM stock.
benzinga.com Short Seller Report Alleges ADMA Biologics Financial Misrepresentation ADMA Biologics shares drop after Culper Research short report alleges financial misreporting; company pushes back.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com ADMA Responds To Short-Seller Report, Reviewing Assertions For Accuracy ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics,…
- benzinga.com ADMA Biologics Q4 Adj. EPS $0.21 Beats $0.18 Estimate, Sales $139.163M Miss $139.400M Estimate ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.18 by 16.22 percent. This is a 53.57 percent increase over earnings of…
benzinga.com Earnings Breakdown: ADMA Biologics Q4 - benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com Preview: ADMA Biologics's Earnings 
benzinga.com Earnings Scheduled For November 5, 2025 
benzinga.com Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Groupon Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Earnings Scheduled For May 7, 2025